

MARKED-UP COPY OF AMENDED CLAIMS

5. (Amended) The method [of one of claims 1 to 4] claim 1 wherein the water-soluble, nonionic, organic binder is selected from the group consisting of polyvinylpyrrolidone, a water-soluble, nonionic cellulose derivative, and polyvinylalcohol.

7. (Amended) The method of one of [claims 1 to 6] claim 1 wherein the nonionic surfactant is selected from the group consisting of polysorbate, polyoxeyethylenehydrogenated castor oil, and a poloxamer.

8. (Amended) The method of [one of claims 1 to 7] claim 1 wherein drying of the aqueous liquid is performed by spray drying, lyophilization or spray-freeze drying, or by coating which may be fluid-bed coating, or performed in fluid-bed granulation.

9. (Amended) The method of [one of claims 1 to 8] claim 1 wherein the average size of the particles making up the powder is 1-10 μm .

10. (Amended) The method of [one of claims 1 to 9] claim 1 wherein the physiologically active peptide is selected from the group consisting of growth hormones, insulins, calcitonins, erythropoietin, glucagon, somatostatin, somatostatin derivatives, interferons, interleukins, superoxide, dismutase, urokinase, proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors and anti-vasculogenesis factors.

11. (Amended) The method of [one of claims 1 to 9] claim 1 wherein the physiologically active peptide is human growth hormone or human insulin.

12. (Amended) The method [of one of claims 1 to 9] claim 1 wherein the physiologically active peptide is human growth hormone.

17. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 16] claim 13 wherein the water-soluble, nonionic, organic binder is selected from the group consisting of polyvinylpyrrolidone, a water-soluble, nonionic cellulose derivative, and polyvinylalcohol.

19. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 18] claim 13 wherein the nonionic surfactant is selected from the group consisting of polyysorbate, polyoxeyethylenhydrogenated castor oil, and a poloxamer.

20. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 19] claim 13 wherein drying of the aqueous liquid is performed by spray drying, lyophilization or spray-freeze drying, or by coating which may be fluid-bed coating, or performed in fluid-bed granulation.

21. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 20] claim 13 wherein the average size of the particles making up the powder is 1-10 μm .

22. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 21] claim 13 wherein the physiologically active peptide

P20757.A01

is selected from the group consisting of growth hormones, insulins, calcitonins, erythropoietin, glucagon, somatostatin, somatostatin derivatives, interferons, interleukins, superoxide, dismutase, urokinase, proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors and anti-vasculogenesis factors.

23. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 21] claim 13 wherein the physiologically active peptide is human growth hormone or human insulin.

24. (Amended) The method for preparation of a powder containing a physiologically active peptide of [one of claims 13 to 21] claim 13 wherein the physiologically active peptide is human growth hormone.

27. (Amended) The powder containing a physiologically active peptide of claim 25 [or 26] wherein the average size of the particles is 1-10 μm .

28. (Amended) The powder containing a physiologically active peptide of [one of claims 25 to 27] claim 25, for which drying of the aqueous liquid was performed by spray drying, spray-freeze drying, or lyophilization.

29. (Amended) The powder containing a physiologically active peptide of [one of claims 25 to 28] claim 25 wherein the physiologically active peptide is selected from the group consisting of growth hormones, insulins, calcitonins, erythropoietin, glucagon,

P20757.A01

somatostatin, somatostatin derivatives, interferons, interleukins, superoxide, dismutase, urokinase, proteases, tumor necrosis factors, colony-stimulating factors, kallikrein, lysozyme, fibronectin, insulin-like growth factors, epidermal growth factor, fibroblast growth factors, platelet-derived growth factor, nerve growth factor, hepatocyte growth factor, vasculogenesis factors and anti-vasculogenesis factors.

30. (Amended) The powder containing a physiologically active peptide of [one of claims 25 to 28] claim 25 wherein the physiologically active peptide is human growth hormone or human insulin.

31. (Amended) The powder containing a physiologically active peptide of [one of claims 25 to 28] claim 25 wherein the physiologically active peptide is human growth hormone.

32. (Amended) An inhalant composition containing a physiologically active peptide, wherein the inhalant composition comprises particles as defined in [one of claims 25 to 31] claim 25.